{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hereditary+Hemorrhagic+Telangiectasia",
    "query": {
      "condition": "Hereditary Hemorrhagic Telangiectasia"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hereditary+Hemorrhagic+Telangiectasia&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:59:50.249Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05406362",
      "title": "Assess Safety and Efficacy of VAD044 in HHT Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia (HHT)"
      ],
      "interventions": [
        {
          "name": "VAD044 Part I",
          "type": "DRUG"
        },
        {
          "name": "VAD044 Part II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vaderis Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2022-07-18",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-05-21T23:59:50.249Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05406362"
    },
    {
      "nct_id": "NCT03850964",
      "title": "Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia",
        "Epistaxis",
        "Anemia",
        "Nosebleed",
        "HHT"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cure HHT",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 70,
      "start_date": "2023-05-08",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-05-21T23:59:50.249Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Denver, Colorado • Augusta, Georgia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03850964"
    },
    {
      "nct_id": "NCT00684879",
      "title": "Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Osler-Rendu-Weber Disease",
        "Osler-Rendu Disease",
        "Telangiectasia, Hereditary Hemorrhagic"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2008-05-21",
      "completion_date": "2016-01-07",
      "has_results": false,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-05-21T23:59:50.249Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00684879"
    },
    {
      "nct_id": "NCT01408732",
      "title": "Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epistaxis",
        "Hereditary Hemorrhagic Telangiectasia"
      ],
      "interventions": [
        {
          "name": "Sclerotherapy",
          "type": "DRUG"
        },
        {
          "name": "Standard Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2011-02",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2019-11-01",
      "last_synced_at": "2026-05-21T23:59:50.249Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01408732"
    },
    {
      "nct_id": "NCT07474428",
      "title": "Quality of Life in Pediatric Participants With HHT",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hereditary Haemorrhagic Telangiectasia (HHT)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ashley Nelson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 70,
      "start_date": "2026-07",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-05-21T23:59:50.249Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07474428"
    },
    {
      "nct_id": "NCT02204371",
      "title": "Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Telangiectasia, Hereditary Hemorrhagic"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 7,
      "start_date": "2015-02-25",
      "completion_date": "2016-02-10",
      "has_results": true,
      "last_update_posted_date": "2017-07-06",
      "last_synced_at": "2026-05-21T23:59:50.249Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02204371"
    },
    {
      "nct_id": "NCT00470977",
      "title": "Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Coats' Disease",
        "Idiopathic Retinal Telangiectasia",
        "Retinal Angiomatous Proliferation",
        "Polypoidal Choroidal Vasculopathy",
        "Pseudoxanthoma Elasticum",
        "Pathological Myopia",
        "Multi-focal Choroiditis",
        "Rubeosis Iridis",
        "Von Hippel Lindau Disease",
        "BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)"
      ],
      "interventions": [
        {
          "name": "ranibizumab injection (0.5 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Manhattan Eye, Ear & Throat Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2007-05",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2012-10-25",
      "last_synced_at": "2026-05-21T23:59:50.249Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00470977"
    },
    {
      "nct_id": "NCT07018401",
      "title": "Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia (HHT)"
      ],
      "interventions": [
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 62,
      "start_date": "2024-05-01",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-05-21T23:59:50.249Z",
      "location_count": 11,
      "location_summary": "San Diego, California • San Francisco, California • Gainesville, Florida + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07018401"
    },
    {
      "nct_id": "NCT01397695",
      "title": "Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia (HHT)"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-06",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-05-21T23:59:50.249Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397695"
    },
    {
      "nct_id": "NCT04167085",
      "title": "NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Epistaxis"
      ],
      "interventions": [
        {
          "name": "Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2017-12-18",
      "completion_date": "2021-06-01",
      "has_results": true,
      "last_update_posted_date": "2022-07-20",
      "last_synced_at": "2026-05-21T23:59:50.249Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04167085"
    }
  ]
}